ABBV
Morning caffeine, pharma edition
AbbVie is expected to step up to the earnings mic before the market opens on April 29, and that usually means one thing: everyone’s about to squint at the numbers and the guidance like it’s a crossword puzzle with money attached.
Why you should care
This isn’t just a routine check-in. AbbVie has been juggling the usual big-pharma cocktail of patent fears, pipeline bets, and enough regulatory headlines to make your head spin. So when Q1 2026 lands, investors will be looking for signs that the core business is still doing the heavy lifting while the company keeps feeding the growth beast.
What’s in the spotlight
A few things are likely to matter most:
- whether revenue growth is still running strong enough to calm the “what happens after Humira?” crowd
- how new and expanding products are trending
- whether management nudges full-year guidance up, down, or into the corporate version of “we’ll circle back”
Big picture
Pre-earnings reports like this are basically the financial equivalent of waiting outside the principal’s office. The number itself matters, sure — but the real investor question is whether AbbVie can keep proving it’s more than one old blockbuster and a lot of nostalgia.